psoriasis pipeline insight

DelveInsight’s, “Psoriasis- Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Psoriasis: Understanding

Psoriasis: Overview

Psoriasis is a chronic, inflammatory skin disorder characterized by the rapid buildup of skin cells, leading to red, scaly patches commonly found on the elbows, knees, scalp, and back. This condition is driven by an overactive immune response that accelerates skin cell production, creating raised, itchy plaques. While the exact cause remains unknown, genetics, immune system dysfunction, and environmental triggers such as stress, infections, or injuries play significant roles. Psoriasis can range from mild to severe, impacting quality of life and often associated with other health issues like psoriatic arthritis, cardiovascular disease, and mental health challenges.

 

Psoriasis presents with distinctive signs and symptoms, including red patches of skin covered by thick, silvery scales, primarily appearing on areas like the scalp, elbows, knees, and lower back. These plaques can be itchy, painful, and may crack or bleed. Some individuals also experience nail changes, such as pitting, discoloration, and separation from the nail bed, known as nail psoriasis. In addition to physical symptoms, people with psoriasis may feel a burning or stinging sensation in affected areas, particularly during flare-ups triggered by stress, infections, or skin injuries.

Psoriasis affects approximately 2-3% of the global population, translating to over 125 million people worldwide. In the United States alone, around 7.5 million people are impacted by this chronic inflammatory condition, with about 20-30% of cases classified as moderate to severe.

 

The pathology of psoriasis involves complex immune dysregulation that accelerates skin cell turnover, causing characteristic plaques. Normally, skin cells take weeks to mature and shed, but in psoriasis, this process shortens to days due to immune system activation, particularly by T-cells, which mistakenly target skin cells as if healing a wound or fighting an infection. This immune response releases cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukins (IL-17, IL-23), which drive inflammation and stimulate the rapid production of new skin cells. This results in the buildup of immature cells on the skin surface, forming red, scaly patches.

The diagnosis of psoriasis typically involves a physical examination of the skin, scalp, and nails, where a healthcare provider looks for characteristic red, scaly patches and other signs like nail pitting or separation. A family history of psoriasis or related conditions may also aid in the diagnosis. In some cases, a skin biopsy is performed, where a small sample of the affected skin is examined under a microscope to differentiate psoriasis from other skin disorders with similar symptoms, like eczema. Psoriasis has several subtypes, including plaque, guttate, inverse, pustular, and erythrodermic psoriasis, each with distinct features that can guide treatment.

 

Psoriasis treatment aims to manage symptoms, reduce flare-ups, and improve quality of life, as there is currently no cure. Mild cases are often treated with topical therapies, such as corticosteroids, vitamin D analogs, and retinoids, which help reduce inflammation and slow skin cell turnover. For moderate to severe cases, systemic treatments like methotrexate, cyclosporine, and biologics—targeting specific immune pathways, such as TNF-α or interleukins (IL-17, IL-23)—are commonly used to suppress immune responses and reduce inflammation.

 

"Psoriasis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.

 

Psoriasis Emerging Drugs Chapters

This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Psoriasis Emerging Drugs

• Piclidenoson: Can-Fite Biopharma

Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis.

 

• Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie's Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.

 

• QY101: E-nitiate Biopharmaceuticals

QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.

 

• SFA 002: SFA Therapeutics

SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.

 

• RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.

Further product details are provided in the report……..

 

Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Psoriasis

There are approx. 65+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Phase III include, Can-Fite Biopharma.

 

Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.

 

Psoriasis Report Insights

• Psoriasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Psoriasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriasis drugs?
• How many Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?